INTRODUCTION: We evaluated serum C-telopeptides (CTX) to see whether they may be useful as predictive markers for disease progression in cancer patients with bone metastases who are being treated with zoledronic acid (ZA). PATIENTS AND METHODS: This was a prospective, nonrandomised study in which 26 patients with solid tumours and confirmed bone metastases were treated with ZA (4 mg every 3-4 weeks) for 24 months or until a skeletal-related event (SRE) was observed. Serum CTX levels were determined at baseline and 6, 12, 18 and 24 months after study initiation. SRE were evaluated using bone scintigraphy. RESULTS: Study participants had prostate (50%), breast (31%), lung (11%) or bladder (8%) tumours. Mean age was 69 (range 52-84) years, and 65% men. At baseline, overall mean CTX levels were 562.47 ± 305.17 pg/dl. Patients who showed disease progression during the study period showed significantly higher CTX levels at baseline and after 18 months of ZA treatment than patients who did not progress (p = 0.040 and p = 0.006, respectively). Patients with ≥ 5 bone metastases at diagnosis had significantly higher CTX levels after 18 months of ZA treatment than patients with < 5 bone metastasis (p = 0.001). Similarly, at 12 and 18 months, patients without SRE had significantly lower CTX levels than patients in whom a SRE was observed (p = 0.005 and p = 0.001, respectively). CONCLUSIONS: Changes in serum CTX levels seem to predict the potential for tumour control and the likelihood of developing an SRE in a sample of patients with solid tumours and bone metastases treated with ZA.
INTRODUCTION: We evaluated serum C-telopeptides (CTX) to see whether they may be useful as predictive markers for disease progression in cancerpatients with bone metastases who are being treated with zoledronic acid (ZA). PATIENTS AND METHODS: This was a prospective, nonrandomised study in which 26 patients with solid tumours and confirmed bone metastases were treated with ZA (4 mg every 3-4 weeks) for 24 months or until a skeletal-related event (SRE) was observed. Serum CTX levels were determined at baseline and 6, 12, 18 and 24 months after study initiation. SRE were evaluated using bone scintigraphy. RESULTS: Study participants had prostate (50%), breast (31%), lung (11%) or bladder (8%) tumours. Mean age was 69 (range 52-84) years, and 65% men. At baseline, overall mean CTX levels were 562.47 ± 305.17 pg/dl. Patients who showed disease progression during the study period showed significantly higher CTX levels at baseline and after 18 months of ZA treatment than patients who did not progress (p = 0.040 and p = 0.006, respectively). Patients with ≥ 5 bone metastases at diagnosis had significantly higher CTX levels after 18 months of ZA treatment than patients with < 5 bone metastasis (p = 0.001). Similarly, at 12 and 18 months, patients without SRE had significantly lower CTX levels than patients in whom a SRE was observed (p = 0.005 and p = 0.001, respectively). CONCLUSIONS: Changes in serum CTX levels seem to predict the potential for tumour control and the likelihood of developing an SRE in a sample of patients with solid tumours and bone metastases treated with ZA.
Authors: Hans D Menssen; Adriana Sakalová; Aurélie Fontana; Zuzana Herrmann; Christian Boewer; Thierry Facon; Michail R Lichinitser; C R J Singer; Liana Euller-Ziegler; Marc Wetterwald; Denis Fiere; Mikulás Hrubisko; Eckhard Thiel; Pierre D Delmas Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: A Lipton; L Demers; E Curley; V Chinchilli; L Gaydos; G Hortobagyi; R Theriault; D Clemens; L Costa; J Seaman; R Knight Journal: Eur J Cancer Date: 1998-12 Impact factor: 9.162
Authors: Leo Widler; Knut A Jaeggi; Markus Glatt; Klaus Müller; Rolf Bachmann; Michael Bisping; Anne-Ruth Born; Reto Cortesi; Gabriela Guiglia; Heidi Jeker; Rémy Klein; Ueli Ramseier; Johann Schmid; Gerard Schreiber; Yves Seltenmeyer; Jonathan R Green Journal: J Med Chem Date: 2002-08-15 Impact factor: 7.446
Authors: Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman Journal: J Clin Oncol Date: 2003-08-15 Impact factor: 44.544
Authors: Robert Coleman; Janet Brown; Evangelos Terpos; Allan Lipton; Matthew R Smith; Richard Cook; Pierre Major Journal: Cancer Treat Rev Date: 2008-06-24 Impact factor: 12.111
Authors: B E Hillner; J N Ingle; J R Berenson; N A Janjan; K S Albain; A Lipton; G Yee; J S Biermann; R T Chlebowski; D G Pfister Journal: J Clin Oncol Date: 2000-03 Impact factor: 44.544
Authors: Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen Journal: J Natl Cancer Inst Date: 2002-10-02 Impact factor: 13.506
Authors: Maria A Lopez-Olivo; Nimit A Shah; Greg Pratt; Jan M Risser; Elaine Symanski; Maria E Suarez-Almazor Journal: Support Care Cancer Date: 2012-09-07 Impact factor: 3.603
Authors: A Alcaraz; R González-López; J Morote; C de la Piedra; C Meseguer; E Esteban; M Climent; B González-Gragera; J-L Alvarez-Ossorio; I Chirivella; B Mellado; P-C Lara; F Vázquez; J-A Contreras; J Carles; A Murias; V Calderero; J Comet-Batlle; A González-Del Alba; L León-Mateos; A Mañas; J Segarra; A Lassa; C González-Enguita; M-J Méndez; P Samper; M Unda; I Mahillo-Fernández; J Bellmunt Journal: Br J Cancer Date: 2013-06-25 Impact factor: 7.640
Authors: A Beltran-Bless; M Murshed; M Zakikhani; I Kuchuk; N Bouganim; S Robertson; N Kekre; L Vandermeer; J Li; C L Addison; F Rauch; M Clemons; R Kremer Journal: Bone Rep Date: 2021-10-22